TICKERNOMICS Sign up
Last Update: 2024-12-27 15:22:32
BRUKER CORP ( BRKR ) https://www.bruker.com
58.31USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-20.72%
BRKR
SPY
32.66%
-28.20%
BRKR
SPY
108.59%
BRKR
16.84%
SPY
302.52%
BRKR
211.82%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
8670.70
10819.90
0.82
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
28.44
2.68
4.70
1.50
0.34
63.95
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
7.88
48.45
5.20
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.3248
11.44
8.67
1.36
Other Earnings and Cash Flow Stats:
BRUKER CORP ( BRKR ) Net Income TTM ($MM) is 304.90
BRUKER CORP ( BRKR ) Operating Income TTM ($MM) is 288.60
BRUKER CORP ( BRKR ) Owners' Earnings Annual ($MM) is 0.00
BRUKER CORP ( BRKR ) Current Price to Owners' Earnings ratio is 0.00
BRUKER CORP ( BRKR ) EBITDA TTM ($MM) is 325.90
BRUKER CORP ( BRKR ) EBITDA Margin is 5.20%
Capital Allocation:
BRUKER CORP ( BRKR ) has paid 0.20 dividends per share and bought back -1.4 million shares in the past 12 months
BRUKER CORP ( BRKR ) has increased its debt by 1077.699999 million USD in the last 12 months
Capital Structure:
BRUKER CORP ( BRKR ) Interest-bearing Debt ($MM) as of last quarter is 2297
BRUKER CORP ( BRKR ) Annual Working Capital Investments ($MM) are -454
BRUKER CORP ( BRKR ) Book Value ($MM) as of last quarter is 1843
BRUKER CORP ( BRKR ) Debt/Capital as of last quarter is 127%
Other Balance Sheet Stats:
BRUKER CORP ( BRKR ) has 148 million in cash on hand as of last quarter
BRUKER CORP ( BRKR ) has 1322 million of liabilities due within 12 months, and long term debt 2290 as of last quarter
BRUKER CORP ( BRKR ) has 148 common shares outstanding as of last quarter
BRUKER CORP ( BRKR ) has 0 million USD of preferred stock value
Academic Scores:
BRUKER CORP ( BRKR ) Altman Z-Score is 2.61 as of last quarter
BRUKER CORP ( BRKR ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
BRUKER CORP ( BRKR ) largest shareholder is owning shares at 0.00 ($MM) value
PACKER RICHARD A(an insider) Sold 3350 shares of BRUKER CORP ( BRKR ) for the amount of $193682.60 on 2024-12-02
31.84% of BRUKER CORP ( BRKR ) is held by insiders, and 79.12% is held by institutions
BRUKER CORP ( BRKR ) went public on 2000-08-04
Other BRUKER CORP ( BRKR ) financial metrics:
FCF:156.70
Unlevered Free Cash Flow:0.00
EPS:1.10
Operating Margin:7.88
Gross Profit Margin:48.45
Div. Payout Ratio%:9.75
Div. Growth YoY%:0.00
Equity Return%:9.05
Beta:1.36
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BRUKER CORP ( BRKR ) :
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.